We are live on
!
Find out more
TC
TFS Capital Portfolio holdings
AUM
$255M
1-Year Est. Return
32.31%
This Fund
S&P 500
This Quarter
Est. Return
+13.38%
1 Year Est. Return
+32.31%
3 Year Est. Return
+53.79%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.05B
AUM Growth
-$106M
(-9.2%)
Cap. Flow
-$174M
Cap. Flow
% of AUM
-16.63%
Top 10 Holdings %
Top 10 Hldgs %
5.73%
Holding
1,387
New
364
Increased
246
Reduced
349
Closed
422
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
INFI
Infinity Pharmaceuticals, Inc.
INFI
|
+$5.05M |
| 2 |
Century Aluminum
CENX
|
+$4.6M |
| 3 |
CBM
Cambrex Corporation
CBM
|
+$4.54M |
| 4 |
BBBY
Bed Bath & Beyond
BBBY
|
+$4.51M |
| 5 |
MACK
Merrimack Pharmaceuticals, Inc.
MACK
|
+$4.41M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
OneSpan
OSPN
|
+$7.67M |
| 2 |
Lattice Semiconductor
LSCC
|
+$7.09M |
| 3 |
Mercury Insurance
MCY
|
+$5.38M |
| 4 |
Omnicell
OMCL
|
+$5.15M |
| 5 |
Maximus
MMS
|
+$4.88M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.11% |
| 2 | Technology | 14.11% |
| 3 | Consumer Discretionary | 11.34% |
| 4 | Industrials | 10.88% |
| 5 | Financials | 8.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
901
Pacific Biosciences
PACB
$416M
| $112K | 0.01% |
14,346
-24,637
| -63% | -$158K |
|
|
CMLS
902
DELISTED
Cumulus Media Inc. Class A Common Stock
CMLS
| $112K | 0.01% |
+3,301
| New | +$98.2K |
|
|
GTI
903
DELISTED
GRAFTECH INTERNATIONAL LTD
GTI
| $112K | 0.01% |
22,193
-35,173
| -61% | -$154K |
|
904
Protalix BioTherapeutics
PLX
$189M
| $111K | 0.01% |
6,044
-21,109
| -78% | -$453K |
|
|
FSYS
905
DELISTED
FUEL SYSTEMS SOLUTIONS INC COM STK
FSYS
| $110K | 0.01% |
+10,091
| New | +$97.6K |
|
906
Citizens
CIA
$251M
| $106K | 0.01% |
13,962
-1,012
| -7% | -$7.33K |
|
|
SKUL
907
DELISTED
SKULLCANDY INC
SKUL
| $106K | 0.01% |
+11,572
| New | +$98.5K |
|
|
PGTI
908
DELISTED
PGT, Inc.
PGTI
| $104K | 0.01% |
10,760
-33,742
| -76% | -$315K |
|
909
Chegg
CHGG
$121M
| $103K | 0.01% |
+14,845
| New | +$96.1K |
|
|
NETI
910
DELISTED
Eneti Inc.
NETI
| $102K | 0.01% |
464
-110
| -19% | -$46.4K |
|
|
LF
911
DELISTED
LEAPFROG ENTERPRISES INC.
LF
| $102K | 0.01% |
+21,506
| New | +$114K |
|
|
ARTX
912
DELISTED
Arotech Corporation
ARTX
| $99K | 0.01% |
+42,631
| New | +$111K |
|
|
ELOS
913
DELISTED
Syneron Medical Ltd
ELOS
| $99K | 0.01% |
10,633
-355
| -3% | -$3.42K |
|
|
ICAD
914
DELISTED
iCAD Inc
ICAD
| $95K | 0.01% |
10,412
-49,026
| -82% | -$482K |
|
915
Novavax
NVAX
$1.19B
| $95K | 0.01% |
802
-607
| -43% | -$63.4K |
|
916
Veru
VERU
$35.2M
| $95K | 0.01% |
2,413
-1,279
| -35% | -$52.7K |
|
|
TLM
917
DELISTED
TALISMAN ENERGY INC
TLM
| $94K | 0.01% |
+12,024
| New | +$75.5K |
|
|
IID
918
DELISTED
VOYA INTERNATIONAL HIGH DIVIDEND EQUITY INCOME FUND
IID
| $94K | 0.01% |
+11,589
| New | +$101K |
|
|
JMP
919
DELISTED
JMP Group LLC
JMP
| $91K | 0.01% |
+11,973
| New | +$85.8K |
|
|
TLGT
920
DELISTED
Teligent, Inc
TLGT
| $90K | 0.01% |
+1,025
| New | +$96.1K |
|
921
Comstock Resources
CRK
$3.81B
| $88K | 0.01% |
2,587
-34,712
| -93% | -$1.8M |
|
922
Gyre Therapeutics
GYRE
$668M
| $87K | 0.01% |
42
-419
| -91% | -$807K |
|
|
NGD
923
DELISTED
New Gold Inc
NGD
| $87K | 0.01% |
20,195
-3,099
| -13% | -$13.3K |
|
|
NAME
924
DELISTED
Rightside Group, Ltd.
NAME
| $87K | 0.01% |
12,912
-57,680
| -82% | -$510K |
|
|
PACD
925
DELISTED
Pacific Drilling S A
PACD
| $85K | 0.01% |
+1,834
| New | +$118K |
|
Similar funds
KC
IPC
ECPI
FRM
WFG
IFB
KL
RP
TFS Capital's Q4 2014 Portfolio in Review
As of Q4 2014, TFS Capital held 1,387 positions worth $1.05B, down 9.2% from $1.15B the previous quarter. Its ten largest holdings account for 5.7% of the portfolio.
TFS Capital withdrew a net $174M in Q4 2014, closing 422 positions and reducing 349 holdings. Its most notable exit was Lattice Semiconductor, an estimated $7.09M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 14% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, TFS Capital opened a new position in Infinity Pharmaceuticals, Inc. worth $5.86M.
- TFS Capital's largest Q4 2014 buy was Infinity Pharmaceuticals, Inc.: 347,088 shares worth $5.86M.
- TFS Capital added most to Cambrex Corporation in Q4 2014, an estimated $4.54M increase.
- TFS Capital's biggest Q4 2014 reduction was OneSpan, cutting an estimated $7.67M.
- TFS Capital fully exited Lattice Semiconductor in Q4 2014, selling an estimated $7.09M.
- TFS Capital's ten largest holdings make up 5.7% of its $1.05B portfolio in Q4 2014.
- TFS Capital opened 364 new positions and closed 422 in Q4 2014.
- TFS Capital's portfolio value fell 9.2% quarter-over-quarter to $1.05B.
Based on TFS Capital's 13F filing for Q4 2014, filed 29 Jan 2015.